Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Radiation Therapy in the Management of Oligometastatic Breast Cancer: Current Evidence and Future Directions

Radiation Therapy in the Management of Oligometastatic Breast Cancer: Current Evidence and Future... Purpose of ReviewTo review the role of radiation therapy and specifically metastasis-directed stereotactic body radiation therapy (SBRT) in the management of patients with oligometastatic breast cancer with emphasis on potential toxicities and future directions.Recent FindingsRecent prospective studies have demonstrated encouraging initial results indicating the potential efficacy of metastasis-directed SBRT in the management of patients with oligometastatic disease. However, given potentially significant toxicities associated with metastasis-directed SBRT, additional data in the form of phase III randomized control trials are needed to define the role of SBRT in the management of patients with oligometastatic breast cancer; such studies are currently ongoing.SummaryWhile current data are encouraging, additional data are required to determine the benefit of SBRT in patients with oligometastatic breast cancer. Physicians opting to treat patients with metastasis-directed SBRT should ideally do so on protocol. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Current Breast Cancer Reports Springer Journals

Radiation Therapy in the Management of Oligometastatic Breast Cancer: Current Evidence and Future Directions

Loading next page...
 
/lp/springer-journals/radiation-therapy-in-the-management-of-oligometastatic-breast-cancer-SThauQtvbu
Publisher
Springer Journals
Copyright
Copyright © Springer Science+Business Media, LLC, part of Springer Nature 2020
ISSN
1943-4588
eISSN
1943-4596
DOI
10.1007/s12609-020-00383-y
Publisher site
See Article on Publisher Site

Abstract

Purpose of ReviewTo review the role of radiation therapy and specifically metastasis-directed stereotactic body radiation therapy (SBRT) in the management of patients with oligometastatic breast cancer with emphasis on potential toxicities and future directions.Recent FindingsRecent prospective studies have demonstrated encouraging initial results indicating the potential efficacy of metastasis-directed SBRT in the management of patients with oligometastatic disease. However, given potentially significant toxicities associated with metastasis-directed SBRT, additional data in the form of phase III randomized control trials are needed to define the role of SBRT in the management of patients with oligometastatic breast cancer; such studies are currently ongoing.SummaryWhile current data are encouraging, additional data are required to determine the benefit of SBRT in patients with oligometastatic breast cancer. Physicians opting to treat patients with metastasis-directed SBRT should ideally do so on protocol.

Journal

Current Breast Cancer ReportsSpringer Journals

Published: Oct 4, 2020

There are no references for this article.